← Russell 3000 cross-section

ALKS Alkermes plc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-28, not restated
Healthcare

Scale

Market cap
$8.2bn
Revenue TTM
$1.7bn
Net income TTM
$66m
Free cash flow
$222m
Composite score
40.7
Sector rank
#812

Valuation

P / E
124.7
EV / EBITDA
50.7
EV / sales
5.4
FCF yield
2.69%
Earnings yield vs 10-yr
-3.93pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
4.0%
EBITDA margin
10.7%
ROE
3.7%
ROIC
4.5%
Revenue growth
10.8%

Insider activity, last 90 days

Net open-market
$-4.27m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Executive Summary Net income was $0.5 million or $0.00 per ordinary share—basic and diluted, for the three months ended June 30, 2026 and net loss was $66.0 million or $0.40 per ordinary share—basic and diluted, for the six months ended June 30, 2026, compared to net income of $87.1 million and $109.6 million or $0.53 and $0.67 per ordinary share—basic and $0.52 and $0.65 per ordinary share—diluted, for the three and six months ended June 30, 2025, respectively. …Alkermes plc., 10-Q, period ended 2026-06-30, filed 2026-07-28

Read the full passage →